{
  "source": "PA-Notification-Kerendia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1376-4\nProgram Prior Authorization/Notification\nMedication Kerendia® (finerenone)\nP&T Approval Date 12/2021, 12/2022, 1/2024, 10/2024\nEffective Date 2/1/2025\n1. Background:\nKerendia (finerenone) is indicated to reduce the risk of sustained estimated glomerular filtration\nrate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial\ninfarction, and hospitalization for heart failure in adult patients with chronic kidney disease\n(CKD) associated with type 2 diabetes (T2D).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Kerendia will be approved based on all of the following criteria:\na. Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D)\n-AND–\nb. Both of the following:\n1) Urinary albumin-to-creatinine ratio (UACR) of greater than or equal to 30 mg/g\n-AND-\n2) An eGFR of greater than or equal to 25 mL/min/1.73 m2\n-AND-\nc. Used to reduce the risk of any of the following:\n1) Sustained eGFR decline\n2) End-stage kidney disease\n3) Cardiovascular death\n4) Non-fatal myocardial infarction\n5) Hospitalization for heart failure\nAuthorization will be issued for 12 months\n© 2024 UnitedHealthcare Services Inc.\n1\nB. Reauthorization\n1. Kerendia will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits or Prior Authorization/Medical",
    "ion history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits or Prior Authorization/Medical Necessity may be in place.\n4. References:\n1. Kerendia [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.\nSeptember 2022.\n2. Bakris, GL, Agarwal R, Anker SD, Effect of Finerenone on Chronic Kidney Disease\nOutcomes in Type 2 Diabetes. NEJM. 2020; 383:2219-29.\n3. de Boer, IH, Khunti, K, Sadusky, T, et al. Diabetes Management in Chronic Kidney\nDisease: A Consensus Report by the American Diabetes Association (ADA) and Kidney\nDisease: Improving Global Outcomes (KDIGO). Diabetes Care 2022.\n4. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic\nKidney Disease. Kidney International. 2024 (105): S114-314\nProgram Prior Authorization/Notification – Kerendia\nChange Control\nDate Change\n12/2021 New program\n12/2022 Based on updated guidelines modified UACR to greater than or equal to\n30 mg/g and eGFR to greater than or equal to 25 mL/min/1.73 m2 for\ndiagnosis of chronic kidney disease and updated policy to change the\nreduction risk criteria from all to any. Increased the initial authorization\nto 6 months. Updated references.\n1/2024 Annual review. Updated references.\n10/2024 Updated diagnosis language. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}